{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T06:15:29Z","timestamp":1788243329982,"version":"build-2803163510"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T00:00:00Z","timestamp":1766016000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T00:00:00Z","timestamp":1768953600000},"content-version":"vor","delay-in-days":34,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-32404-0","type":"journal-article","created":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T23:25:38Z","timestamp":1766013938000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Plasma p-tau217 and p-tau217\/A\u03b21\u201342 ratios associate with medial temporal lobe subfield atrophy in normal aging and mild cognitive impairment"],"prefix":"10.1038","volume":"16","author":[{"given":"Amirhossein","family":"Rabiei rad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Nadaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farbod","family":"Khosravi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamide","family":"Nasiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0188-8438","authenticated-orcid":false,"given":"Arman","family":"Ghayourvahdat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"For the Alzheimer\u2019s Disease Neuroimaging Initiative","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,18]]},"reference":[{"key":"32404_CR1","doi-asserted-by":"crossref","unstructured":"2023 Alzheimer\u2019s disease facts and figures. Alzheimer\u2019s Dement 19 (4), 1598\u20131695 (2023).","DOI":"10.1002\/alz.13016"},{"issue":"1","key":"32404_CR2","doi-asserted-by":"publisher","first-page":"169","DOI":"10.3233\/JAD-190056","volume":"69","author":"WW Li","year":"2019","unstructured":"Li, W. W. et al. Brain Amyloid-\u03b2 deposition and blood biomarkers in patients with clinically diagnosed alzheimer\u2019s disease. J. Alzheimers Dis. 69 (1), 169\u2013178 (2019).","journal-title":"J. Alzheimers Dis."},{"issue":"13","key":"32404_CR3","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1001\/jama.2019.2000","volume":"321","author":"GD Rabinovici","year":"2019","unstructured":"Rabinovici, G. D. et al. Association of amyloid positron emission tomography with subsequent change in clinical management among medicare beneficiaries with mild cognitive impairment or dementia. JAMA 321 (13), 1286\u20131294 (2019).","journal-title":"Jama"},{"key":"32404_CR4","doi-asserted-by":"crossref","unstructured":"Liu, Z. et al. Pathophysiology Characterization of Alzheimer\u2019s Disease in South China\u2019s Aging Population: for the Greater-Bay-Area Healthy Aging Brain Study (GHABS) Vol. 16, 84 (Alzheimer\u2019s Research & Therapy, 2024).","DOI":"10.1186\/s13195-024-01458-z"},{"issue":"1","key":"32404_CR5","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2212948","volume":"388","author":"CH van Dyck","year":"2023","unstructured":"van Dyck, C. H. et al. Lecanemab in early Alzheimer\u2019s disease. N. Engl. J. Med. 388 (1), 9\u201321 (2023).","journal-title":"N Engl. J. Med."},{"issue":"6","key":"32404_CR6","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1001\/jama.2023.13239","volume":"330","author":"JR Sims","year":"2023","unstructured":"Sims, J. R. et al. Donanemab in early symptomatic alzheimer disease: The TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA 330 (6), 512\u2013527 (2023).","journal-title":"Jama"},{"key":"32404_CR7","doi-asserted-by":"crossref","unstructured":"Consortium, A. B. et al. A framework of biomarkers for brain aging: a consensus statement by the aging biomarker consortium. Life Med. 2 (3) (2023).","DOI":"10.1093\/lifemedi\/lnad033"},{"issue":"12","key":"32404_CR8","doi-asserted-by":"publisher","first-page":"2555","DOI":"10.1038\/s41591-022-02074-w","volume":"28","author":"NJ Ashton","year":"2022","unstructured":"Ashton, N. J. et al. Differential roles of A\u03b242\/40, p-tau231 and p-tau217 for alzheimer\u2019s trial selection and disease monitoring. Nat. Med. 28 (12), 2555\u20132562 (2022).","journal-title":"Nat. Med."},{"issue":"5","key":"32404_CR9","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1002\/ana.25334","volume":"84","author":"IMW Verberk","year":"2018","unstructured":"Verberk, I. M. W. et al. Plasma amyloid as prescreener for the earliest alzheimer pathological changes. Ann. Neurol. 84 (5), 648\u2013658 (2018).","journal-title":"Ann. Neurol."},{"key":"32404_CR10","doi-asserted-by":"crossref","unstructured":"Pichet Binette, A. et al. Combining Plasma Phospho-tau and Accessible Measures to Evaluate Progression to Alzheimer\u2019s Dementia in Mild Cognitive Impairment Patients Vol. 14, 46 (Alzheimer\u2019s Research & Therapy, 2022).","DOI":"10.1186\/s13195-022-00990-0"},{"issue":"6","key":"32404_CR11","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1038\/s41591-021-01348-z","volume":"27","author":"S Palmqvist","year":"2021","unstructured":"Palmqvist, S. et al. Prediction of future Alzheimer\u2019s disease dementia using plasma phospho-tau combined with other accessible measures. Nat. Med. 27 (6), 1034\u20131042 (2021).","journal-title":"Nat. Med."},{"issue":"4","key":"32404_CR12","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1001\/jamaneurol.2022.5272","volume":"80","author":"N Mattsson-Carlgren","year":"2023","unstructured":"Mattsson-Carlgren, N. et al. Prediction of longitudinal cognitive decline in preclinical alzheimer disease using plasma biomarkers. JAMA Neurol. 80 (4), 360\u2013369 (2023).","journal-title":"JAMA Neurol."},{"issue":"1","key":"32404_CR13","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/S1474-4422(21)00361-6","volume":"21","author":"CE Teunissen","year":"2022","unstructured":"Teunissen, C. E. et al. Blood-based biomarkers for Alzheimer\u2019s disease: Towards clinical implementation. Lancet Neurol. 21 (1), 66\u201377 (2022).","journal-title":"Lancet Neurol."},{"issue":"4","key":"32404_CR14","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1212\/WNL.0000000000207193","volume":"101","author":"D Alcolea","year":"2023","unstructured":"Alcolea, D. et al. Blood biomarkers in neurodegenerative diseases: Implications for the clinical neurologist. Neurology 101 (4), 172\u2013180 (2023).","journal-title":"Neurology"},{"issue":"7691","key":"32404_CR15","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/nature25456","volume":"554","author":"A Nakamura","year":"2018","unstructured":"Nakamura, A. et al. High performance plasma amyloid-\u03b2 biomarkers for Alzheimer\u2019s disease. Nature 554 (7691), 249\u2013254 (2018).","journal-title":"Nature"},{"issue":"1","key":"32404_CR16","doi-asserted-by":"publisher","first-page":"26801","DOI":"10.1038\/srep26801","volume":"6","author":"S Janelidze","year":"2016","unstructured":"Janelidze, S. et al. Plasma \u03b2-amyloid in Alzheimer\u2019s disease and vascular disease. Sci. Rep. 6 (1), 26801 (2016).","journal-title":"Sci. Rep."},{"issue":"5","key":"32404_CR17","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1002\/alz.12841","volume":"19","author":"NJ Ashton","year":"2023","unstructured":"Ashton, N. J. et al. Plasma and CSF biomarkers in a memory clinic: Head-to-head comparison of phosphorylated Tau immunoassays. Alzheimers Dement. 19 (5), 1913\u20131924 (2023).","journal-title":"Alzheimers Dement."},{"issue":"17","key":"32404_CR18","doi-asserted-by":"publisher","first-page":"e1647","DOI":"10.1212\/WNL.0000000000008081","volume":"93","author":"SE Schindler","year":"2019","unstructured":"Schindler, S. E. et al. High-precision plasma \u03b2-amyloid 42\/40 predicts current and future brain amyloidosis. Neurology 93 (17), e1647\u2013e1659 (2019).","journal-title":"Neurology"},{"key":"32404_CR19","doi-asserted-by":"crossref","unstructured":"Montoliu-Gaya, L. et al. Blood biomarkers for Alzheimer\u2019s disease in down syndrome. J. Clin. Med., 10 (16) (2021).","DOI":"10.3390\/jcm10163639"},{"issue":"11","key":"32404_CR20","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1001\/jamaneurol.2021.3180","volume":"78","author":"S Janelidze","year":"2021","unstructured":"Janelidze, S. et al. Head-to-Head comparison of 8 plasma Amyloid-\u03b2 42\/40 assays in alzheimer disease. JAMA Neurol. 78 (11), 1375\u20131382 (2021).","journal-title":"JAMA Neurol."},{"issue":"1","key":"32404_CR21","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1186\/s13195-021-00939-9","volume":"13","author":"S Bayoumy","year":"2021","unstructured":"Bayoumy, S. et al. Clinical and analytical comparison of six Simoa assays for plasma P-tau isoforms P-tau181, P-tau217, and P-tau231. Alzheimers Res. Ther. 13 (1), 198 (2021).","journal-title":"Alzheimers Res. Ther."},{"issue":"5","key":"32404_CR22","doi-asserted-by":"publisher","first-page":"e671","DOI":"10.1212\/WNL.0000000000011226","volume":"96","author":"I Ill\u00e1n-Gala","year":"2021","unstructured":"Ill\u00e1n-Gala, I. et al. Plasma Tau and neurofilament light in frontotemporal Lobar degeneration and alzheimer disease. Neurology 96 (5), e671\u2013e683 (2021).","journal-title":"Neurology"},{"issue":"11","key":"32404_CR23","doi-asserted-by":"publisher","first-page":"3170","DOI":"10.1093\/brain\/awaa329","volume":"143","author":"CE Teunissen","year":"2020","unstructured":"Teunissen, C. E., Thijssen, E. H. & Verberk, I. M. W. Plasma p-tau217: From \u2018new kid\u2019 to most promising candidate for Alzheimer\u2019s disease blood test. Brain 143 (11), 3170\u20133172 (2020).","journal-title":"Brain"},{"issue":"5","key":"32404_CR24","doi-asserted-by":"publisher","first-page":"e17123","DOI":"10.15252\/emmm.202217123","volume":"15","author":"G Salvad\u00f3","year":"2023","unstructured":"Salvad\u00f3, G. et al. Specific associations between plasma biomarkers and postmortem amyloid plaque and Tau tangle loads. EMBO Mol. Med. 15 (5), e17123 (2023).","journal-title":"EMBO Mol. Med."},{"issue":"4","key":"32404_CR25","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1093\/brain\/awac333","volume":"146","author":"S Janelidze","year":"2023","unstructured":"Janelidze, S. et al. Head-to-head comparison of 10 plasma phospho-tau assays in prodromal alzheimer\u2019s disease. Brain 146 (4), 1592\u20131601 (2023).","journal-title":"Brain"},{"key":"32404_CR26","doi-asserted-by":"crossref","unstructured":"Ashton, N. J. et al. Diagnostic accuracy of the plasma ALZpath pTau217 immunoassay to identify Alzheimer\u2019s disease pathology. medRxiv (2023).","DOI":"10.1101\/2023.07.11.23292493"},{"issue":"3","key":"32404_CR27","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1002\/alz.12706","volume":"19","author":"NC Cullen","year":"2023","unstructured":"Cullen, N. C. et al. Test-retest variability of plasma biomarkers in alzheimer\u2019s disease and its effects on clinical prediction models. Alzheimers Dement. 19 (3), 797\u2013806 (2023).","journal-title":"Alzheimers Dement."},{"issue":"9","key":"32404_CR28","first-page":"1797","volume":"28","author":"M Mil\u00e0-Alom\u00e0","year":"2022","unstructured":"Mil\u00e0-Alom\u00e0, M. et al. Plasma p-tau231 and p-tau217 as state markers of amyloid-\u03b2 pathology in preclinical alzheimer\u2019s disease. Nat. Med. 28 (9), 1797\u20131801 (2022).","journal-title":"Nat. Med."},{"issue":"1","key":"32404_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00401-023-02570-4","volume":"146","author":"L Yu","year":"2023","unstructured":"Yu, L. et al. Plasma p-tau181 and p-tau217 in discriminating PART, AD and other key neuropathologies in older adults. Acta Neuropathol. 146 (1), 1\u201311 (2023).","journal-title":"Acta Neuropathol."},{"issue":"1","key":"32404_CR30","doi-asserted-by":"publisher","first-page":"355","DOI":"10.3233\/ADR-230029","volume":"7","author":"MV Pais","year":"2023","unstructured":"Pais, M. V., Forlenza, O. V. & Diniz, B. S. Plasma biomarkers of alzheimer\u2019s disease: A review of available Assays, recent Developments, and implications for clinical practice. J. Alzheimers Dis. Rep. 7 (1), 355\u2013380 (2023).","journal-title":"J. Alzheimers Dis. Rep."},{"issue":"5","key":"32404_CR31","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.1093\/brain\/awad042","volume":"146","author":"CR Jack","year":"2023","unstructured":"Jack, C. R. et al. Predicting amyloid PET and Tau PET stages with plasma biomarkers. Brain 146 (5), 2029\u20132044 (2023).","journal-title":"Brain"},{"issue":"2","key":"32404_CR32","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1001\/jamaneurol.2022.4485","volume":"80","author":"J Therriault","year":"2023","unstructured":"Therriault, J. et al. Association of phosphorylated Tau biomarkers with amyloid positron emission tomography vs Tau positron emission tomography. JAMA Neurol. 80 (2), 188\u2013199 (2023).","journal-title":"JAMA Neurol."},{"key":"32404_CR33","doi-asserted-by":"crossref","unstructured":"Therriault, J. et al. Equivalence of Plasma p-tau217 with Cerebrospinal Fluid in the Diagnosis of Alzheimer\u2019s Disease Vol. 19, 4967\u20134977 (Alzheimer\u2019s & Dementia, 2023).","DOI":"10.1002\/alz.13026"},{"issue":"1","key":"32404_CR34","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s13195-022-01005-8","volume":"14","author":"C Groot","year":"2022","unstructured":"Groot, C. et al. Diagnostic and prognostic performance to detect alzheimer\u2019s disease and clinical progression of a novel assay for plasma p-tau217. Alzheimers Res. Ther. 14 (1), 67 (2022).","journal-title":"Alzheimers Res. Ther."},{"issue":"8","key":"32404_CR35","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1001\/jama.2020.12134","volume":"324","author":"S Palmqvist","year":"2020","unstructured":"Palmqvist, S. et al. Discriminative accuracy of plasma Phospho-tau217 for alzheimer disease vs other neurodegenerative disorders. JAMA 324 (8), 772\u2013781 (2020).","journal-title":"Jama"},{"issue":"12","key":"32404_CR36","doi-asserted-by":"publisher","first-page":"2669","DOI":"10.1002\/alz.12756","volume":"18","author":"O Hansson","year":"2022","unstructured":"Hansson, O. et al. The Alzheimer\u2019s association appropriate use recommendations for blood biomarkers in alzheimer\u2019s disease. Alzheimers Dement. 18 (12), 2669\u20132686 (2022).","journal-title":"Alzheimers Dement."},{"key":"32404_CR37","doi-asserted-by":"crossref","unstructured":"Battineni, G. et al. Improved Alzheimer\u2019s disease detection by mri using multimodal machine learning algorithms. Diagnostics (Basel) 11 (11) (2021).","DOI":"10.3390\/diagnostics11112103"},{"issue":"6","key":"32404_CR38","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1002\/alz.12079","volume":"16","author":"R de Flores","year":"2020","unstructured":"de Flores, R. et al. Contribution of mixed pathology to medial Temporal lobe atrophy in alzheimer\u2019s disease. Alzheimers Dement. 16 (6), 843\u2013852 (2020).","journal-title":"Alzheimers Dement."},{"key":"32404_CR39","doi-asserted-by":"publisher","first-page":"117931","DOI":"10.1016\/j.neuroimage.2021.117931","volume":"233","author":"A Bussy","year":"2021","unstructured":"Bussy, A. et al. Hippocampal subfield volumes across the healthy lifespan and the effects of MR sequence on estimates. Neuroimage 233, 117931 (2021).","journal-title":"Neuroimage"},{"key":"32404_CR40","doi-asserted-by":"crossref","unstructured":"Lenhart, L. et al. Anatomically standardized detection of MRI atrophy patterns in early-stage Alzheimer\u2019s disease. Brain Sci. 11 (11) (2021).","DOI":"10.3390\/brainsci11111491"},{"issue":"1","key":"32404_CR41","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1002\/hipo.23259","volume":"31","author":"SM Stark","year":"2021","unstructured":"Stark, S. M., Frithsen, A. & Stark, C. E. L. Age-related alterations in functional connectivity along the longitudinal axis of the hippocampus and its subfields. Hippocampus 31 (1), 11\u201327 (2021).","journal-title":"Hippocampus"},{"key":"32404_CR42","doi-asserted-by":"publisher","first-page":"1402573","DOI":"10.3389\/fnagi.2024.1402573","volume":"16","author":"F Karimani","year":"2024","unstructured":"Karimani, F. et al. Impairment of entorhinal cortex network activity in alzheimer\u2019s disease. Front. Aging Neurosci. 16, 1402573 (2024).","journal-title":"Front. Aging Neurosci."},{"issue":"7","key":"32404_CR43","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1212\/WNL.34.7.939","volume":"34","author":"G McKhann","year":"1984","unstructured":"McKhann, G. et al. Clinical diagnosis of Alzheimer\u2019s disease: report of the NINCDS-ADRDA work group under the auspices of department of health and human services task force on Alzheimer\u2019s disease. Neurology 34 (7), 939\u2013944 (1984).","journal-title":"Neurology"},{"issue":"3","key":"32404_CR44","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1212\/WNL.0b013e3181cb3e25","volume":"74","author":"RC Petersen","year":"2010","unstructured":"Petersen, R. C. et al. Alzheimer\u2019s disease neuroimaging initiative (ADNI): clinical characterization. Neurology 74 (3), 201\u2013209 (2010).","journal-title":"Neurology"},{"issue":"9","key":"32404_CR45","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1111\/j.1532-5415.1992.tb01992.x","volume":"40","author":"TN Tombaugh","year":"1992","unstructured":"Tombaugh, T. N. & McIntyre, N. J. The mini-mental state examination: A comprehensive review. J. Am. Geriatr. Soc. 40 (9), 922\u2013935 (1992).","journal-title":"J. Am. Geriatr. Soc."},{"issue":"3","key":"32404_CR46","first-page":"pCd010783","volume":"2015","author":"I Arevalo-Rodriguez","year":"2015","unstructured":"Arevalo-Rodriguez, I. et al. Mini-Mental state examination (MMSE) for the detection of Alzheimer\u2019s disease and other dementias in people with mild cognitive impairment (MCI). Cochrane Datab. Syst. Rev. 2015 (3), pCd010783 (2015).","journal-title":"Cochrane Database Syst. Rev."},{"key":"32404_CR47","doi-asserted-by":"crossref","unstructured":"Mitchell, A. J. The mini-mental state examination (MMSE): Update on its diagnostic accuracy and clinical utility for cognitive disorders, in Cognitive Screening Instruments: A Practical Approach (ed Larner, A. J.) 37\u201348 (Springer, 2017).","DOI":"10.1007\/978-3-319-44775-9_3"},{"issue":"1","key":"32404_CR48","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1002\/hbm.22627","volume":"36","author":"PA Yushkevich","year":"2015","unstructured":"Yushkevich, P. A. et al. Automated volumetry and regional thickness analysis of hippocampal subfields and medial Temporal cortical structures in mild cognitive impairment. Hum. Brain Mapp. 36 (1), 258\u2013287 (2015).","journal-title":"Hum. Brain Mapp."},{"issue":"3","key":"32404_CR49","doi-asserted-by":"publisher","first-page":"907","DOI":"10.3233\/JAD-231114","volume":"98","author":"J Cao","year":"2024","unstructured":"Cao, J. et al. The hippocampal subfield volume reduction and plasma biomarker changes in mild cognitive impairment and Alzheimer\u2019s disease. J. Alzheimers Dis. 98 (3), 907\u2013923 (2024).","journal-title":"J. Alzheimers Dis."},{"key":"32404_CR50","doi-asserted-by":"publisher","first-page":"264","DOI":"10.3389\/fnagi.2014.00264","volume":"6","author":"O Voevodskaya","year":"2014","unstructured":"Voevodskaya, O. et al. The effects of intracranial volume adjustment approaches on multiple regional MRI volumes in healthy aging and Alzheimer\u2019s disease. Front. Aging Neurosci. 6, 264 (2014).","journal-title":"Front. Aging Neurosci."},{"issue":"5","key":"32404_CR51","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/S1474-4422(20)30071-5","volume":"19","author":"TK Karikari","year":"2020","unstructured":"Karikari, T. K. et al. Blood phosphorylated Tau 181 as a biomarker for alzheimer\u2019s disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts. Lancet Neurol. 19 (5), 422\u2013433 (2020).","journal-title":"Lancet Neurol."},{"issue":"3","key":"32404_CR52","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1038\/s41591-020-0755-1","volume":"26","author":"S Janelidze","year":"2020","unstructured":"Janelidze, S. et al. Plasma P-tau181 in Alzheimer\u2019s disease: Relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer\u2019s dementia. Nat. Med. 26 (3), 379\u2013386 (2020).","journal-title":"Nat. Med."},{"issue":"11","key":"32404_CR53","doi-asserted-by":"publisher","first-page":"3234","DOI":"10.1093\/brain\/awaa286","volume":"143","author":"N Mattsson-Carlgren","year":"2020","unstructured":"Mattsson-Carlgren, N. et al. Longitudinal plasma p-tau217 is increased in early stages of alzheimer\u2019s disease. Brain 143 (11), 3234\u20133241 (2020).","journal-title":"Brain"},{"issue":"3","key":"32404_CR54","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/s41591-020-0762-2","volume":"26","author":"EH Thijssen","year":"2020","unstructured":"Thijssen, E. H. et al. Diagnostic value of plasma phosphorylated tau181 in Alzheimer\u2019s disease and frontotemporal Lobar degeneration. Nat. Med. 26 (3), 387\u2013397 (2020).","journal-title":"Nat. Med."},{"issue":"3","key":"32404_CR55","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/j.neuroimage.2011.03.028","volume":"56","author":"SG Mueller","year":"2011","unstructured":"Mueller, S. G. et al. Evidence for functional specialization of hippocampal subfields detected by MR subfield volumetry on high resolution images at 4 T. Neuroimage 56 (3), 851\u2013857 (2011).","journal-title":"Neuroimage"},{"key":"32404_CR56","doi-asserted-by":"crossref","unstructured":"La Joie, R. et al. Prospective Longitudinal Atrophy in Alzheimer\u2019s Disease Correlates with the Intensity and Topography of Baseline Tau-PET. Sci. Transl. Med. 12 (524) (2020).","DOI":"10.1126\/scitranslmed.aau5732"},{"issue":"3","key":"32404_CR57","first-page":"pCd009628","volume":"3","author":"G Lombardi","year":"2020","unstructured":"Lombardi, G. et al. Structural magnetic resonance imaging for the early diagnosis of dementia due to alzheimer\u2019s disease in people with mild cognitive impairment. Cochrane Datab. Syst. Rev. 3 (3), pCd009628 (2020).","journal-title":"Cochrane Database Syst. Rev."},{"issue":"11","key":"32404_CR58","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1002\/hipo.20573","volume":"19","author":"F Shi","year":"2009","unstructured":"Shi, F. et al. Hippocampal volume and asymmetry in mild cognitive impairment and alzheimer\u2019s disease: Meta-analyses of MRI studies. Hippocampus 19 (11), 1055\u20131064 (2009).","journal-title":"Hippocampus"},{"issue":"4","key":"32404_CR59","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/S0896-6273(02)00830-9","volume":"35","author":"N Burgess","year":"2002","unstructured":"Burgess, N., Maguire, E. A. & O\u2019Keefe, J. The human hippocampus and Spatial and episodic memory. Neuron 35 (4), 625\u2013641 (2002).","journal-title":"Neuron"},{"issue":"32","key":"32404_CR60","doi-asserted-by":"publisher","first-page":"14466","DOI":"10.1073\/pnas.1004243107","volume":"107","author":"K Igl\u00f3i","year":"2010","unstructured":"Igl\u00f3i, K. et al. Lateralized human hippocampal activity predicts navigation based on sequence or place memory. Proc. Natl. Acad. Sci. U S A. 107 (32), 14466\u201314471 (2010).","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"issue":"Pt B","key":"32404_CR61","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.neuropsychologia.2016.08.016","volume":"93","author":"A Ezzati","year":"2016","unstructured":"Ezzati, A. et al. Differential association of left and right hippocampal volumes with verbal episodic and Spatial memory in older adults. Neuropsychologia 93 (Pt B), 380\u2013385 (2016).","journal-title":"Neuropsychologia"},{"issue":"1","key":"32404_CR62","doi-asserted-by":"publisher","first-page":"2612","DOI":"10.1038\/s41467-020-15701-2","volume":"11","author":"JW Vogel","year":"2020","unstructured":"Vogel, J. W. et al. Spread of pathological Tau proteins through communicating neurons in human Alzheimer\u2019s disease. Nat. Commun. 11 (1), 2612 (2020).","journal-title":"Nat. Commun."},{"issue":"1","key":"32404_CR63","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1073\/pnas.0135058100","volume":"100","author":"MD Greicius","year":"2003","unstructured":"Greicius, M. D. et al. Functional connectivity in the resting brain: A network analysis of the default mode hypothesis. Proc. Natl. Acad. Sci. U S A. 100 (1), 253\u2013258 (2003).","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"32404_CR64","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/j.neuroimage.2015.01.004","volume":"111","author":"PA Yushkevich","year":"2015","unstructured":"Yushkevich, P. A. et al. Quantitative comparison of 21 protocols for labeling hippocampal subfields and parahippocampal subregions in in vivo MRI: Towards a harmonized segmentation protocol. Neuroimage 111, 526\u2013541 (2015).","journal-title":"Neuroimage"},{"issue":"8","key":"32404_CR65","doi-asserted-by":"publisher","first-page":"1971","DOI":"10.1038\/s41591-023-02450-0","volume":"29","author":"S Palmqvist","year":"2023","unstructured":"Palmqvist, S. et al. Cognitive effects of lewy body pathology in clinically unimpaired individuals. Nat. Med. 29 (8), 1971\u20131978 (2023).","journal-title":"Nat. Med."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-32404-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-32404-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-32404-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T00:07:52Z","timestamp":1769213272000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-32404-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,18]]},"references-count":65,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["32404"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-32404-0","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,18]]},"assertion":[{"value":"28 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study was conducted following the Declaration of Helsinki. All ADNI data used were de-identified, and the use of these data for research purposes was approved by the Alzheimer\u2019s Disease Neuroimaging Initiative (ADNI) Data Sharing and Publications Committee.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"As this study utilized pre-existing datasets obtained from an online repository using previously conducted research, direct informed consent from participants was not applicable. However, all datasets were originally collected in compliance with ethical standards, including obtaining informed consent from participants at the time of data acquisition. The current analysis adhered strictly to ethical guidelines, ensuring that all data remained anonymized and deidentified, with no potential for re-identification of participants. Relevant approvals for the use of these datasets were obtained where required, and the study was conducted following the principles outlined in the Declaration of Helsinki.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}],"article-number":"2692"}}